ReViral, a clinical-stage biopharmaceutical company focused on discovering and developing antiviral therapeutics that target (RSV) respiratory syncytial virus has confirmed the FDA has granted Fast Track designation to Sisunatovir.

Sisunatovir is orally administered and is for the treatment of patients with serious RSV infection. Richmond Pharmacology is proud to have supported the development by conducting the First in Human Study earlier in the drug development.

RSV affects approximately 64 million people and causes approximately 160,000 deaths each year. Fast Track is a process intended to facilitate the development and expediate the review of drug candidates that treat serious conditions and fill an unmet medical need.

Latest news

Clinical trials: how taking the pills can pay those bills.

April 20, 2022
The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers
Read more

Clinical trials and the patient perspective

May 6, 2022
Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event